Agnes B Jousset
Overview
Explore the profile of Agnes B Jousset including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Perez-Palacios P, Girlich D, Soraa N, Lamrani A, Maoulainine F, Bennaoui F, et al.
J Glob Antimicrob Resist
. 2023 Mar;
33:208-217.
PMID: 36868310
Objectives: Neonatal sepsis caused by multidrug-resistant (MDR) bacteria has a high morbidity and mortality, especially in low- and middle-income countries. Here, the molecular mechanisms of multidrug resistance in bacteria responsible...
12.
Jousset A, Poignon C, Yilmaz S, Bleibtreu A, Emeraud C, Girlich D, et al.
J Antimicrob Chemother
. 2023 Mar;
78(4):1125-1127.
PMID: 36864015
No abstract available.
13.
Jousset A, Bernabeu S, Emeraud C, Bonnin R, Lomont A, Zahar J, et al.
J Glob Antimicrob Resist
. 2023 Jan;
32:78-84.
PMID: 36708769
Objectives: Ceftolozane-tazobactam (C/T) proved its efficacy for the treatment of infections caused by non-carbapenemase producing Pseudomonas aeruginosa and Enterobacterales. Here, we aimed to provide susceptibility data on a large series...
14.
Bonnin R, Bernabeu S, Emeraud C, Naas T, Girlich D, Jousset A, et al.
Antibiotics (Basel)
. 2023 Jan;
12(1).
PMID: 36671303
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’s class...
15.
Polyclonal Dissemination of OXA-232 Carbapenemase-Producing Klebsiella pneumoniae, France, 2013-2021
Emeraud C, Birer A, Girlich D, Jousset A, Creton E, Naas T, et al.
Emerg Infect Dis
. 2022 Oct;
28(11):2304-2307.
PMID: 36286195
During 2013-2021, increased prevalence of oxacillinase 232-producing Enterobacterales was observed in France, mostly driven by its emergence in Klebsiella pneumoniae. Whole-genome sequencing identified that oxacillinase 232-producing K. pneumoniae belonged to...
16.
Bonnin R, Bernabeu S, Emeraud C, Creton E, Vanparis O, Naas T, et al.
Int J Antimicrob Agents
. 2022 Aug;
60(4):106660.
PMID: 35988666
Relebactam and vaborbactam are among the newest β-lactamase inhibitors marketed. They were originally designed to inhibit the Ambler class A carbapenemase KPC. In this study, susceptibility to imipenem/relebactam and meropenem/vaborbactam...
17.
Emeraud C, Godmer A, Girlich D, Vanparis O, Mahamdi F, Creton E, et al.
J Antimicrob Chemother
. 2022 Jul;
77(10):2835-2839.
PMID: 35815675
Background: Despite the fact that carbapenem-resistant Enterobacterales (CRE) mostly cause urinary tract infections (UTIs), only few studies have focused on the efficacity of mecillinam against these CRE. Objectives: To evaluate...
18.
Bonnin R, Emeraud C, Jousset A, Naas T, Dortet L
Clin Microbiol Infect
. 2022 May;
28(8):1156.e1-1156.e5.
PMID: 35533970
Objectives: Cefiderocol is a catechol-substituted cephalosporin dedicated to the treatment of infections caused by multidrug resistant gram-negative rods. Cefiderocol susceptibility testing might be complex. We compared cefiderocol susceptibility testing methods...
19.
Emeraud C, Figueiredo S, Bonnin R, Khecharem M, Ouzani S, Leblanc P, et al.
Pathogens
. 2021 Nov;
10(11).
PMID: 34832582
Infections caused by extended-spectrum β-lactamase-producing (ESBL-KP) are constantly rising worldwide and are often reported as causative agent of outbreaks in intensive care units (ICUs). During the first wave of the...
20.
Jousset A, Oueslati S, Emeraud C, Bonnin R, Dortet L, Iorga B, et al.
Antimicrob Agents Chemother
. 2021 Oct;
65(12):e0116021.
PMID: 34606331
Resistance to the ceftazidime (CAZ)-avibactam (AVI) combination is increasingly being reported. Here, we report a CAZ-AVI-resistant Klebsiella pneumoniae strain belonging to the high-risk sequence type 307 (ST307) clone and producing...